Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)

Trial Profile

A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary)
  • Indications Glomerulonephritis; IgA nephropathy; Kidney disorders; Lupus nephritis; Membranoproliferative glomerulonephritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms DISCOVERY
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2019 Status changed from recruiting to active, no longer recruiting.
    • 08 Nov 2019 According to an Apellis Pharmaceuticals media release, detailed preliminary results from the study were presented at the American Society of Nephrology (ASN) Kidney Week 2019.
    • 08 Nov 2019 Preliminary results presented in an Apellis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top